Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viral Structure00:56

Viral Structure

62.2K
Viruses are extraordinarily diverse in shape and size, but they all have several structural features in common. All viruses have a core that contains a DNA- or RNA-based genome. The core is surrounded by a protective coat of proteins called the capsid. The capsid is composed of subunits called capsomeres. The capsid and genome-containing core are together known as the nucleocapsid.
62.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Closely Related <i>Escherichia coli</i> Strains with Multiple Resistances Found on Co-Managed Pig Farms Despite Marked Differences in Farm Antimicrobial Drug Usage.

Veterinary sciences·2026
Same author

Impact of Adeno-Associated Virus Production on Capsid Heterogeneity and Product Quality.

Biotechnology and bioengineering·2026
Same author

Biofilms reshape soil-water dynamics with enhanced vapor adsorption and hysteresis reversal under dry conditions.

NPJ biofilms and microbiomes·2026
Same author

Genome-wide association analyses highlight the role of the intestinal molecular environment in human gut microbiota variation.

Nature genetics·2026
Same author

Partial Freezing Enables Functional Preservation of Kidney Grafts for up to 10 Days.

Research square·2026
Same author

Enumeration of Bacteria in Suspensions Using Time Domain Reflectometry.

ACS measurement science au·2025

Related Experiment Video

Updated: Jul 2, 2025

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors
09:12

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors

Published on: April 5, 2024

2.9K

Analytical characterization of full, intermediate, and empty AAV capsids.

Aisleen McColl-Carboni1, Serena Dollive1, Sarah Laughlin1

  • 1Oxford Biomedica (US) LLC, 1 Patriots Park, Bedford, MA, 01730, USA.

Gene Therapy
|February 20, 2024
PubMed
Summary

Intermediate capsids in adeno-associated virus (AAV) manufacturing contribute to vector genome titer and infectivity but not potency. Controlling these impurities is crucial for developing more efficacious AAV products.

More Related Videos

A Quantitative Dot Blot Assay for AAV Titration and Its Use for Functional Assessment of the Adeno-associated Virus Assembly-activating Proteins
14:49

A Quantitative Dot Blot Assay for AAV Titration and Its Use for Functional Assessment of the Adeno-associated Virus Assembly-activating Proteins

Published on: June 12, 2018

13.8K
Author Spotlight: Advancing Gene Therapy Research with High-Titer Adeno-Associated Virus Vector Production
05:51

Author Spotlight: Advancing Gene Therapy Research with High-Titer Adeno-Associated Virus Vector Production

Published on: May 3, 2024

1.6K

Related Experiment Videos

Last Updated: Jul 2, 2025

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors
09:12

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors

Published on: April 5, 2024

2.9K
A Quantitative Dot Blot Assay for AAV Titration and Its Use for Functional Assessment of the Adeno-associated Virus Assembly-activating Proteins
14:49

A Quantitative Dot Blot Assay for AAV Titration and Its Use for Functional Assessment of the Adeno-associated Virus Assembly-activating Proteins

Published on: June 12, 2018

13.8K
Author Spotlight: Advancing Gene Therapy Research with High-Titer Adeno-Associated Virus Vector Production
05:51

Author Spotlight: Advancing Gene Therapy Research with High-Titer Adeno-Associated Virus Vector Production

Published on: May 3, 2024

1.6K

Area of Science:

  • Biotechnology
  • Gene Therapy
  • Viral Vector Manufacturing

Background:

  • Recombinant adeno-associated virus (AAV) vector production yields full, intermediate, and empty capsids.
  • Intermediate and empty capsids are impurities that may affect AAV product safety and efficacy.
  • These impurities can reduce efficacy by competing for cellular transduction and increase safety concerns due to higher capsid load.

Purpose of the Study:

  • To investigate the impact of intermediate capsids on the potency of AAV products.
  • To determine if intermediate capsids contribute to the biological activity and efficacy of AAV vectors.

Main Methods:

  • Separation of an AAV preparation into fractions enriched for full, intermediate, or empty capsids.
  • Utilized a comprehensive panel of in vitro assays (infectivity, gene expression, biological activity).
  • Employed in vivo potency assays to assess AAV product performance based on capsid content.

Main Results:

  • Intermediate capsids were found to contribute to the vector genome titer.
  • Intermediate capsids demonstrated infectivity comparable to full capsids.
  • Crucially, intermediate capsids did not contribute to the overall potency of the AAV product.

Conclusions:

  • Intermediate capsids, despite being infectious, do not enhance AAV product potency.
  • Reducing and controlling intermediate capsid levels is essential for manufacturing efficacious AAV gene therapy products.
  • This study highlights the importance of capsid purity for optimal AAV vector performance.